Results 1 to 10 of about 27,323 (260)

Chemical‐Assembled Macrophage‐Engaging Glypican‐3 × Signal Regulatory Protein‐α (SIRP‐α) Bispecific Antibody for Immunotherapy Against Liver Cancer [PDF]

MedComm
Bispecific antibodies (BsAbs) represent a growing class of cancer immunotherapeutics, yet their wider adoption remains limited by complex recombinant production and limited manufacturing efficiency.
Bo Tang, Wing Hei Leung, Chihao Shao, Dongfang Li, Kwai Man Lau, Macro K. H. Lui, Jingyi Liu, Jacky C. H. Chu, Clare S. W. Yan, Chi‐Ming Che, Xuechen Li, Wing‐Tak Wong, Larry Ming Cheung Chow, Terence K. W. Lee, Clarence T. T. Wong   +14 more
doaj   +2 more sources

Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody

Cancer Management and Research, 2023
Darren Pan, Joshua Richter Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USACorrespondence: Darren Pan, One Gustave L.
Joshua Richter, Darren Pan
exaly   +2 more sources

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity

Life, 2022
B7-H3 plays an important role in tumor apoptosis, proliferation, adhesion, angiogenesis, invasion, migration, and evasion of immune surveillance. It is overexpressed in various human solid tumor tissues.
Yan Feng, Kun Xie, Yanxin Yin, Bingyu Li, Chenyu Pi, Xiaoqing Xu, Tao Huang, Jingming Zhang, Bo Wang, Hua Gu, Jianmin Fang   +10 more
doaj   +1 more source

Production of native bispecific antibodies in rabbits. [PDF]

PLoS ONE, 2010
BACKGROUND: A natural bispecific antibody, which can be produced by exchanging Fab arms of two IgG4 molecules, was first described in allergic patients receiving therapeutic injections with two distinct allergens.
Wei Wang, Ruihuan Xu, Jinming Li
doaj   +1 more source

Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis

Fluids and Barriers of the CNS, 2022
Background Treatment with amyloid-β (Aβ) targeting antibodies is a promising approach to remove Aβ brain pathology in Alzheimer's disease (AD) and possibly even slow down or stop progression of the disease.
Ulrika Julku, Mengfei Xiong, Elin Wik, Sahar Roshanbin, Dag Sehlin, Stina Syvänen   +5 more
doaj   +1 more source

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau

Frontiers in Nuclear Medicine, 2023
IntroductionAlzheimer's disease (AD) is characterized by the misfolding and aggregation of two major proteins: amyloid-beta (Aβ) and tau. Antibody-based PET radioligands are desirable due to their high specificity and affinity; however, antibody uptake ...
Vinay Banka, Andrew Kelleher, Dag Sehlin, Greta Hultqvist, Einar M. Sigurdsson, Einar M. Sigurdsson, Stina Syvänen, Yu-Shin Ding   +7 more
doaj   +1 more source

Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins

mAbs, 2021
Bispecific antibodies have recently attracted intense interest. CrossMab technology was described in 2011 as novel approach enabling correct antibody light-chain association with their respective heavy chain in bispecific antibodies, together with ...
Marlena Surowka, Wolfgang Schaefer, Christian Klein   +2 more
doaj   +1 more source

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth

Journal for ImmunoTherapy of Cancer, 2020
Background Small cell lung cancer (SCLC) accounts for 15% of lung cancers, and the primary treatment of this malignancy is chemotherapy and radiotherapy.
Xin Chen, Norhan Amar, Yuankui Zhu, Chunguang Wang, Chunjiao Xia, Xiaoqing Yang, Dongde Wu, Mingqian Feng   +7 more
doaj   +1 more source

Bispecific antibodies

Drug Discovery Today, 2015
Bispecific antibodies have emerged as molecules with a multitude of ...
Kontermann, Roland E., Brinkmann, Ulrich
openaire   +6 more sources

Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. [PDF]

PLoS ONE, 2018
Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin conjugates against Muc1 have not shown significant efficacy for tumors with Muc1 overexpression.
Yumei Li, Changhua Zhou, Jing Li, Jiayu Liu, Limin Lin, Li Li, Donglin Cao, Qing Li, Zhong Wang   +8 more
doaj   +1 more source